Japan Launch- 15 Million cash milestone from Abbott now official.
Another 15million in Sucampo's cash box cant hurt..
Japan's FIRST prescription drug for this ailment...
Having solid company like Abbott as the partner in Japan gives potential for a nice,new steady revenue stream for Sucampo.
These revs coming online in Q4. Japan has highest per capita pharmaceutical use in the the world. $15M milestone could get them to profitable quarter. Two follow-on sNDA approvals on tap between now and January for Amitiza and Rescula.
Lack of PPS movement today was unreal opportunity to buy more.